- Report
- August 2025
- 182 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 188 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 189 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 191 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 189 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 197 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 194 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 190 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 194 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 194 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 199 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 182 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 196 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 198 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- May 2024
- 200 Pages
Global
From €3711EUR$4,150USD£3,173GBP
- Report
- May 2024
- 200 Pages
Global
From €3711EUR$4,150USD£3,173GBP
- Report
- August 2023
- 145 Pages
Global
From €2817EUR$3,150USD£2,408GBP
- Report
- July 2024
- 150 Pages
Global
From €3354EUR$3,750USD£2,867GBP
- Report
- July 2024
- 150 Pages
Global
From €3354EUR$3,750USD£2,867GBP
- Report
- July 2024
- 100 Pages
Global
From €3354EUR$3,750USD£2,867GBP

The Drug Eluting Balloon (DEB) market is a subset of the medical device industry. DEBs are used to treat peripheral artery disease (PAD) and coronary artery disease (CAD). They are designed to deliver a drug directly to the site of the blockage, allowing for improved efficacy and reduced side effects. DEBs are typically composed of a balloon catheter with a drug-eluting coating. The drug is released when the balloon is inflated, allowing for targeted delivery of the drug to the affected area.
DEBs have been shown to be effective in treating PAD and CAD, and are increasingly being used in clinical practice. They offer a minimally invasive alternative to traditional treatments such as stenting and bypass surgery.
Some companies in the DEB market include Medtronic, Boston Scientific, Abbott, and B. Braun. Show Less Read more